Expanded Access to COVID Therapies in Centralized Hub
Anaqua’s ideaPoint, a provider of medical affairs and innovation management solutions, announced a strategic partnership with clinical data company WideTrial to facilitate greater access to investigational medicines for physicians and patients dealing with COVID-19 worldwide.
The project’s objective is to establish a single centralized hub for access to potentially effective COVID-19 therapeutics through established Expanded Access (EA) regulations. While pharma manufacturers are not enforced to allow EA access to their investigational drugs, the hub is designed to handle demand if EAP are granted. The new platform is designed to allow interested healthcare providers (including non-traditional trial sites, community hospitals, and clinics) to sign up online to participate in the EAPs.
For more information, click here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
